Japan Bio Products Co., Ltd. (JBP)
Laennec
Brand
Japan Bio Products Co., Ltd. (JBP)
Category
IV Therapy
Origin
Korea
Interested in ordering Laennec? Send an enquiry and our team will follow up with availability and pricing.
Used in
Overview
Laennec is a human placenta hydrolysate injection manufactured by Japan Bio Products Co., Ltd. (JBP) using proprietary extraction technology. In Japan it is a long-established pharmaceutical whose approved indication is improvement of hepatic function in chronic hepatic disease, and it is also used internationally in revitalisation and anti-ageing protocols. As a human-derived biologic, its regulatory status and permitted use vary significantly by country.
How it works
Laennec is a water-soluble hydrolysate of human placenta containing low-molecular-weight peptides, amino acids, nucleic acid components, trace elements and other bioactive constituents. It is marketed for cellular revitalisation and hepatic support, with proposed activity in supporting tissue repair and metabolic function. Mechanistic claims for placental extracts remain an area of ongoing study and vary by jurisdiction.
Indications
- Improvement of hepatic function in chronic hepatic disease (approved indication in Japan)
- Revitalisation and anti-ageing support
- General wellness and vitality programmes
- Fatigue and recovery support
- Skin quality and rejuvenation protocols (per market positioning)
Key features
- Human placenta hydrolysate, 112 mg / 2 mL ampoule
- Manufactured by JBP (Japan Bio Products) under Japanese GMP
- Long-established pharmaceutical history in Japan
- Administered SC or IM
- Approved in Japan for improvement of hepatic function in chronic hepatic disease
Benefits
- Recognised Japanese-origin placental extract for revitalisation menus
- Established manufacturer with long production history supports provenance
- Fits premium anti-ageing and wellness positioning
- Defined dosing guidance supports protocol standardisation
- Single-use ampoules support controlled administration
Composition
Water-soluble human placenta hydrolysate 112 mg per 2 mL ampoule.
Usage & handling
Administered subcutaneously or intramuscularly under medical supervision; the standard adult dose is 2 mL once daily, increased to 2-3 times daily according to symptoms per the manufacturer. IMPORTANT: as a human placenta-derived biologic, regulatory status differs by country - it is restricted or unapproved in some jurisdictions, and recipients may face blood/plasma donation deferral in certain countries. Verify national regulatory approval, import rules and donation-deferral implications before any clinical use.
For medical professionals. Product information is for reference and does not replace the manufacturer's instructions for use. Availability and regulatory status vary by region.